Treatment-free Remission Accomplished With Dasatinib in Patients With CML

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

131 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-10-31

Study Completion Date

2021-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to find out how to increase the potential for achieving an "operational cure" from chronic myeloid leukemia. An "operational cure" is a state in which a person does not require further treatment, although there may be some remaining cancer cells. Patients would normally remain on a TK inhibitor indefinitely within a standard of care setting for chronic myeloid leukemia. Within this clinical trial, patients will discontinue their TK inhibitor prematurely. If any signs of progression are identified, dasatinib will be introduced.

This research is being done because dasatinib has been shown to achieve a greater response in a much higher proportion of patients as compared to imatinib. Dasatinib is approximately 300 times more potent than imatinib, and it is possible that a greater response can be achieved by dasatinib than by imatinib.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia-CP Who Have Maintained Complete Molecular Remission for Two Years; Dasatinib Stop Trial

NCT01627132

Chronic Myeloid Leukemia

UNKNOWN PHASE2

Treating Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) With Dasatinib

NCT02348957

Myeloid Leukemia, Chronic, Chronic-Phase

COMPLETED

Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia

NCT03216070

Chronic Myelogenous Leukemia

UNKNOWN PHASE4

Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response

NCT01850004

Chronic Phase Chronic Myeloid Leukemia

COMPLETED PHASE2

Front-line Treatment of BCR-ABL+ Chronic Myeloid Leukemia (CML) With Dasatinib

NCT01761890

Chronic Myeloid Leukemia

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is an open label, single arm Phase II trial that will examine how safe and effective it will be for patients with chronic myeloid leukemia (CML) to discontinued first line tyrosine kinase inhibitor (TKI) therapy.

The main goal of this study is to determine the potential role of dasatinib (the study drug) in helping patients with CML attain a sustained treatment free remission.

During this study the safety and tolerability of Dasatinib will be evaluated by means of drug related toxicity, adverse event reports, physical examinations and laboratory safety evaluations.

The study period for an individual patient is expected to be approximately between 30-72 months.

A total of 135 patients will be recruited from 10 Canadian centres.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Myeloid Leukemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Dasatinib

This research is being done because dasatinib has been shown to achieve a deep molecular response in patients as compared to imatinib.

Patients in this study will continue to take their own supply of imatinib for three months to ensure they have achieved a stable response to the drug. Once this has been confirmed, imatinib will be stopped and the patients in this study will then be monitored to see if their CML relapses. This period can last up to 2.5 years.

If the participant has a relapse, they will be started on dasatinib and will continue to receive dasatinib for up to 2 years.

If after one year they achieve a response, they will continue on dasatinib for one more year. If the participant maintains this response, they will have the option of discontinuing dasatinib.

Group Type OTHER

Dasatinib

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dasatinib

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Sprycel

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Diagnosis of CML
2. Treatment of chronic phase CML treated for a minimum of three years exclusively with imatinib
3. Levels of BCR-ABL by RQ-PCR with ≥ 4.5 log reduction from baseline
4. Provide written informed consent
5. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
6. Age \>18 years.
7. Adequate organ liver and renal functions
8. Normal serum levels (within normal limits)

Exclusion Criteria

1. Prior treatment with a TKI (except for imatinib, hydroxyurea, anagrelide or interferon)
2. Taking any medications or substances known to affect CYP3A4.
3. Concurrent medical condition which may increase the risk of toxicity
4. History of significant bleeding disorder unrelated to cancer
5. Cardiac Symptoms
6. Clinically significant hypokalemia or hypomagnesemia that cannot be corrected prior to dasatinib administration

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No